life.
science.
discovery.

MBL International provides high-quality products and solutions to advance life science research and clinical diagnostics.

Learn More

Product Highlight

MHC Tetramers

MHC Tetramers and Monomers for high specificity immune monitoring.

Patented α3 mutation for reduced background.

Click for Details

Product Highlight

Autophagy

Simplify your autophagy research using our well trusted and reliable autophagy kits and antibodies.

Explore autophagy targets including LC3, p62, Atg8 and other related products.

Learn More

Download

Tetramer Staining Guide

MBL International’s new Tetramer Staining Guide is a collection of protocols and data to help make your experiments a success.

Click below for more details and to receive a digital version.

Click for Details

Product Highlight

IL-18

MBL International’s IL-18 products are highly cited and widely trusted.

We offer a wide range of antibodies, ELISA kits and recombinant proteins.

Learn More

Product Highlight

News

MBL International will be attending AAI 2019 in San Diego, CA on May 9 through May 13.

Come by our booth # 1037 and learn how we can help your research needs.

Learn More
  • Spotlight
  • Promotions
  • Services
  • News + Events
  • New Products
  • Blog

Novel Neoantigen Screening Tool:  QuickSwitch™ Custom Tetramer Kits

A rapid high throughput and user friendly system for creating new tetramer specificities. Tetramers resulting from peptide exchange with selected peptides can be used for immune monitoring.

Useful for research involving cancer neoantigens, infectious agents and many other research areas.

Learn more about our QuickSwitch™ products.

  • Share your review – write about your experience using an MBLI product and receive an award. Terms and Conditions apply.

 

 

MBL International is here to work with you and advance your unique research needs using custom services. We can help with Immuno-monitoring services using MHC Tetramers and Cytokines.  Contact us today for more information.

MBL International will be exhibiting at the following shows:

May 9 – May 13: Immunology 2019 in San Diego, CA

 

Press Release

JSR’s Life Sciences Division Appoints New CEO for MBL International

 

Jan. 23, 2018 – Sunnyvale, CA – JSR Life Sciences, the life sciences-focused business unit of JSR Corporation, announced today that it has appointed Dr. Nalini Murdter as the President and Chief Executive Officer of MBL International (MBLI) effective immediately.

Read More

May 22nd, 2017: MEDICAL & BIOLOGICAL LABORATORIES Co., Ltd. (MBL) announced that it has entered into a collaboration agreement with the p53 Laboratory, Agency for Science, Technology and Research (A*STAR) in Singapore to establish the novel screening technology which accelerates the drug discovery targeting Protein-Protein Interactions (PPIs).

February 28th, 2017: MEDICAL & BIOLOGICAL LABORATORIES Co., Ltd. concludes a patent licensing agreement with the University of Toyama concerning a rapid antibody production technique

 

 

  • QuickSwitch, a tool for adoptive T cell transfer

    Wed, 24 Apr 2019 17:00:00 GMTBy:

    Our understanding of how the immune system responds to cancer has increased by leaps and bounds in the past two decades, allowing us to develop a new approach to fight cancer that uses the power of the body’s own immune system to prevent, target, control, and eliminate the disease. Collectively, this technique of battling cancer is known as cancer immunotherapy. Such an approach encompasses many methods from broad ones like applying immune checkpoint blockers (ICB) or using monoclonal antibodies (mAbs) that target known cancer antigens to more personalized ones like adoptive T cell transfer including the use of Chimeric antigen receptor (CAR) T cells.
    It is this personalized immunotherapy approach that has sparked a great deal of interest among researchers. This method involves the extraction of a patient’s T cells and the subsequent stimulation of the rare T cells populations that can fight cancer with specific antigens. For this form of therapy to work there needs to be an exact knowledge of the peptide sequences derived from tumor cells (neo-epitopes) that can be used to artificially stimulate a patient’s T cells to fight them.
    Previously, we have described how by using the QuickSwitchTM Quant Platform peptides, they can be tested for their ability to bind MHC Class I molecules. This test does not involve prediction algorithms or large swaths of data with a great deal of false positives but provides an in vitro result of whether or not the peptide can be presented on the MHC molecule in about 8 hours. It is our hope that by using our kit, researchers will be able to discover and validate neoantigen peptide sequences more effectively, which would open up new ways for adoptive T cell transfer in cancer immunotherapy. Read more
  • Stabilizing cellular antigens the easy way using Transfix

    Fri, 29 Mar 2019 17:00:00 GMTBy:

    Many researchers and clinicians have issues with keeping their whole blood or CSF samples viable over time. Whether the reason is because the collection occurred on a Friday afternoon with no lab analysis available until Monday, or collecting a large batch of samples to send out to the lab at the other end or the state, cellular degradation can be a problem. Don’t let this happen to you. Read more
  • Is Wnt3a an essential component in organoid culture?

    Wed, 27 Mar 2019 18:00:00 GMTBy: mmrahman@MBLINTL.COM (M. Mamunur Rahman, PhD)

    Organoids are self-organized three-dimensional tissue cultures that are derived from mammalian pluripotent or adult stem cells. These in-vitro-grown cell clusters are given possibilities to replicate much of the complexity of an organ. There are potentially as many types of organoids as there are different tissues and organs. To date, researchers have been able to prepare brain, kidney, lung, intestine, stomach, liver and many more are developing. Read more

View All